IRadimed Corporation (NASDAQ: IRMD) is a Healthcare company (Medical - Devices) with a market capitalization of $1.1B. The Maz Rating grades it against the other companies in its sector.
IRadimed Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $83.45, IRadimed Corporation trades at 44.2x trailing earnings, 12.0x sales and 10.0x book value, with an EV/EBITDA of 31.5. Over the last twelve months it generated about $89M of revenue and $24M of net income. It runs a gross margin of 75.5%, an operating margin of 32.3% and a net margin of 26.8%. It shows return on equity of 23.9%, return on invested capital of 20.1% and a free cash flow yield of 2.4%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 8.99. Over the past 52 weeks the share price ranged from $76.35 to $107.90, with a beta of 0.91.
IRadimed Corporation pays a dividend yielding 1.56%, with 68% of earnings paid out. Its Maz Dividend Score is 1.10 out of 5, ranked against the other dividend payers in its sector (Safety 2.23, Growth 3.03, Yield 2.23, Consistency 1.03).
2 Wall Street analyst ratings cover the stock: 2 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongside their related accessories and support services, to both U.S. and international markets. Key offerings include the MRidium MRI-compatible intravenous (IV) infusion pump system, which comes with disposable tubing sets, and an MRI-compatible patient vital signs monitoring system. Furthermore, IRADIMED provides a range of complementary items such as non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors. Their clientele primarily consists of hospitals, acute care facilities, and outpatient imaging centers. Sales are conducted via direct field representatives, regional sales directors, clinical support specialists, and independent distributors. Founded in 1992, IRADIMED CORPORATION is headquartered in Winter Springs, Florida.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, IRadimed Corporation (IRMD) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 5.78% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 5.78% / 33% · Receivables / Mkt Cap (36m) 1.25% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 5.78% / 33.33% · Receivables / Mkt Cap (24m) 1.25% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 50.1% / 33.33% · Receivables / Avg Assets (4Q) 11.7% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 52.3% / 33.33% · (Cash+Recv) / Total Assets 63.6% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, IRadimed Corporation (IRMD) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. IRadimed Corporation is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
IRadimed Corporation reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.